We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Regorafenib

News List

Bayer’s Regorafenib is the First Drug to Enter GBM AGILE americanpharmaceuticalreview
November 19, 2018
The Global Coalition for Adaptive Research (GCAR) and Bayer announced that Bayers regorafenib will be the first drug to
Five therapies endorsed for use on NHS Scotland pharmatimes
July 09, 2018
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
NICE gives final draft guidance on two key cancer drugs pharmafile
October 13, 2017
NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the treatment of gastrointestinal stromal tumours (GIST
Bayer receives EU approval for Regorafenib europeanpharmaceuticalreview
August 09, 2017
Bayer have announced the European Commission has granted marketing authorisation for Stivarga…